

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087406 A1

(51) International Patent Classification⁷: **C12Q 1/68**,
G01N 33/53, 33/68, A01K 67/027, A61K 35/00

(21) International Application Number: PCT/EP03/04058

(22) International Filing Date: 17 April 2003 (17.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02008701.1 18 April 2002 (18.04.2002) EP
60/373,375 18 April 2002 (18.04.2002) US

(71) Applicant (for all designated States except US): **EVOTEC NEUROSCIENCES GMBH** [DE/DE]; Schnackenburgallee 114, 22525 Hamburg (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HESTERKAMP, Thomas** [DE/DE]; Nordhäuser Weg 18, 22455 Hamburg (DE). **VON DER KAMMER, Heinz** [DE/DE]; Verbindungsstr. 6d, 22607 Hamburg (DE). **KRAPPA, Ralf** [DE/DE]; Rostocker Str. 12, 25436 Tornesch (DE). **POHLNER, Johannes** [DE/DE]; Quittenweg 11, 22175 Hamburg (DE).

(74) Agents: **MEYERS, Hans-Wilhelm** et al.; Patent Attorneys, von Kreisler Selting Werner, P. O. Box 10 22 41, 50462 Cologne (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: DIAGNOSTIC AND THERAPEUTIC USE OF AN ATP-BINDING CASSETTE GENE AND PROTEIN FOR NEURODEGENERATIVE DISEASES

Differential expression of ABCA1 as determined by
RT-PCR analysis



(57) Abstract: The present invention discloses the differential expression of the ABCA1 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the ABCA1 gene and its corresponding gene products. A method of screening for modulating agents of neuro-degenerative diseases is also disclosed.



WO 03/087406 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DIAGNOSTIC AND THERAPEUTIC USE OF AN ATP-BINDING CASSETTE GENE AND PROTEIN FOR NEURODEGENERATIVE DISEASES

The present invention relates to methods of diagnosing, prognosticating, and monitoring the progression of neurodegenerative diseases in a subject. Furthermore, methods of therapy control and screening for modulating agents of neurodegenerative diseases are provided. The invention also discloses pharmaceutical compositions, kits, and recombinant animal models.

Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly debilitating impact on a patient's life. Furthermore, these diseases constitute an enormous health, social, and economic burden. AD is the most common neurodegenerative disease, accounting for about 70% of all dementia cases, and it is probably the most devastating age-related neurodegenerative condition affecting about 10% of the population over 65 years of age and up to 45% over age 85 (for a recent review see Vickers et al., *Progress in Neurobiology* 2000, 60: 139-165). Presently, this amounts to an estimated 12 million cases in the US, Europe, and Japan. This situation will inevitably worsen with the demographic increase in the number of old people ("aging of the baby boomers") in developed countries. The neuropathological hallmarks that occur in the brains of individuals with AD are senile plaques, composed of amyloid- β protein, and profound cytoskeletal changes coinciding with the appearance of abnormal filamentous structures and the formation of neurofibrillary tangles.

The amyloid- β (A β) protein evolves from the cleavage of the amyloid precursor protein (APP) by different kinds of proteases. The cleavage by the β/γ -secretase leads to the formation of A β peptides of different lengths, typically a short more soluble and slow aggregating peptide consisting of 40 amino acids and a longer 42 amino acid peptide, which rapidly aggregates outside the cells, forming the characteristic amyloid plaques (Selkoe, *Physiological Rev* 2001, 81: 741-66; Greenfield et al., *Frontiers Bioscience*

2000, 5: D72-83). Two types of plaques, diffuse plaques and neuritic plaques, can be detected in the brain of AD patients, the latter ones being the classical, most prevalent type. They are primarily found in the cerebral cortex and hippocampus. The neuritic plaques have a diameter of 50µm to 200µm and are composed of insoluble fibrillar amyloids, fragments of dead neurons, of microglia and astrocytes, and other components such as neurotransmitters, apolipoprotein E, glycosaminoglycans, α 1-antichymotrypsin and others. The generation of toxic A β deposits in the brain starts very early in the course of AD, and it is discussed to be a key player for the subsequent destructive processes leading to AD pathology. The other pathological hallmarks of AD are neurofibrillary tangles (NFTs) and abnormal neurites, described as neuropil threads (Braak and Braak, *Acta Neuropathol* 1991, 82: 239-259). NFTs emerge inside neurons and consist of chemically altered tau, which forms paired helical filaments twisted around each other. Along the formation of NFTs, a loss of neurons can be observed. It is discussed that said neuron loss may be due to a damaged microtubule-associated transport system (Johnson and Jenkins, *J Alzheimers Dis* 1996, 1: 38-58; Johnson and Hartigan, *J Alzheimers Dis* 1999, 1: 329-351). The appearance of neurofibrillary tangles and their increasing number correlates well with the clinical severity of AD (Schmitt et al., *Neurology* 2000, 55: 370-376).

AD is a progressive disease that is associated with early deficits in memory formation and ultimately leads to the complete erosion of higher cognitive function. The cognitive disturbances include among other things memory impairment, aphasia, agnosia and the loss of executive functioning. A characteristic feature of the pathogenesis of AD is the selective vulnerability of particular brain regions and subpopulations of nerve cells to the degenerative process. Specifically, the temporal lobe region and the hippocampus are affected early and more severely during the progression of the disease. On the other hand, neurons within the frontal cortex, occipital cortex, and the cerebellum remain largely intact and are protected from neurodegeneration (Terry et al., *Annals of Neurology* 1981, 10: 184-92).

The age of onset of AD may vary within a range of 50 years, with early-onset AD occurring in people younger than 65 years of age, and late-onset of AD

occurring in those older than 65 years. About 10% of all AD cases suffer from early-onset AD, with only 1-2% being familial, inherited cases.

Currently, there is no cure for AD, nor is there an effective treatment to halt the progression of AD or even to diagnose AD ante-mortem with high probability. Several risk factors have been identified that predispose an individual to develop AD, among them most prominently the epsilon 4 allele of the three different existing alleles (epsilon 2, 3, and 4) of the apolipoprotein E gene (ApoE) (Strittmatter et al., *Proc Natl Acad Sci USA* 1993, 90: 1977-81; Roses, *Ann NY Acad Sci* 1998, 855: 738-43). Efforts to detect further susceptibility genes and disease-linked polymorphisms, lead to the assumption that specific regions and genes on human chromosomes 10 and 12 may be associated with late-onset AD (Myers et al., *Science* 2000, 290: 2304-5; Bertram et al., *Science* 2000, 290: 2303; Scott et al., *Am J Hum Genet* 2000, 66: 922-32).

Although there are rare examples of early-onset AD which have been attributed to genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1, the prevalent form of late-onset sporadic AD is of hitherto unknown etiologic origin. The mutations found to date account for only half of the familial AD cases, which is less than 2% of all AD patients. The late onset and complex pathogenesis of neurodegenerative disorders pose a formidable challenge to the development of therapeutic and diagnostic agents. It is crucial to expand the pool of potential drug targets and diagnostic markers. It is therefore an object of the present invention to provide insight into the pathogenesis of neurological diseases and to provide methods, materials, agents, compositions, and animal models which are suited inter alia for the diagnosis and development of a treatment of these diseases. This object has been solved by the features of the independent claims. The subclaims define preferred embodiments of the present invention.

A number of studies on the etiology of AD have pointed to a role of dysregulated cholesterol levels to be associated with an increased risk of developing the disease. This puts AD in the context of other neurodegenerative disorders caused by unique genetic defects in either cholesterol biosynthesis (e.g. Smith-Lemli-Opitz syndrome and desmosterolosis) or intracellular transport of cholesterol (Niemann-Pick Type C disease). However, while the latter syndroms and diseases are autosomal recessive diseases caused by defects in one particular gene only (for review, Nwokoro et al., *Mol. Genet. Metab.* 2001, 74: 105-119), the late onset form of AD is considered to be a complex and genetically heterogeneous disorder caused by widespread polymorphisms with low penetrance but high prevalence (Tanzi and Bertram, *Neuron* 2001, 32: 181-184).

Regarding AD, an early hallmark finding was that a particular allele of the ApoE apolipoprotein, namely the epsilon 4 allele, is associated with an increased risk and early onset of AD (Corder et al., *Science* 1993, 261: 921-923). ApoE is a lipoprotein found at high levels in both, plasma and brain. In peripheral tissues (i.e. outside the liver) it is involved in the degradation of cholesterol- and triglyceride-rich low density lipoprotein (LDL) particles. ApoE can bind to the LDL receptor, and it is the affinity of the binding to this receptor that determines the role of the different allelic ApoE forms in arteriosclerosis and AD, i.e. the epsilon 2 allele has a certain cholesterol lowering effect in plasma and is associated with a decreased risk of AD while the epsilon 4 allele is associated with elevated plasma cholesterol levels and an increased risk of AD (for review, Golde and Eckman, *Drug Discovery Today* 2001, 6: 1049-1055). However, more than 85% of the variability of the plasma cholesterol is independent of the carrier's ApoE genotype (Breslow, *Annu. Rev. Genet.* 2000, 34: 233-254). Furthermore, it is widely agreed that the vast majority of the brain's cholesterol is synthesized in situ (Dietschy and Turley, *Curr. Opin. Lipidol.* 2001, 12: 105-112) and, therefore, the role ApoE is playing in the brain is likely restricted to regional cholesterol redistribution and a potential direct effect on aggregation of APP-derived A beta 40/ A beta 42-peptides (Mahley, *Science* 1988, 240: 622-631; Castano et al., *Biochem. J.* 1995, 306: 599-604).

Recently, it has been recognized that cholesterol levels in the membrane and/or the cellular ratio of free cholesterol to cholesterol esters would directly impact on membrane fluidity and, indirectly, on the processing of the amyloid precursor protein by the counteracting alpha- and beta-/ gamma-secretases. Cholesterol depletion from cells was demonstrated to impair the amyloidogenic beta-/ gamma-secretase-dependent pathway while favoring the non-amyloidogenic alpha-secretase-dependent pathway (Golde and Eckman, *Drug Discovery Today* 2001, 6: 1049-1055; Simons et al., *Neurology* 2001, 57: 1089-1093; Wolozin, *Proc. Natl. Acad. Sci. U.S.A.* 2001, 98: 5371-5373; Puglielli et al., *Nat. Cell Biol.* 2001, 3: 905-912). Together, the picture that emerges is that an overall lowering of cellular cholesterol levels in cells is of benefit with respect to developing AD. This is further and strongly supported by epidemiologic studies using drugs that block de novo synthesis of cholesterol in the whole body, including the brain. Such treatment markedly reduced the incidence of AD in the investigated populations (Wolozin et al., *Arch. Neurol.* 2000, 57: 1439-1443; Jick et al., *Lancet* 2000, 356: 1627-1631). The same beneficial impact of cholesterol lowering drugs was observed in experimental animal models of AD (Refolo et al., *Neurobiol. Dis.* 2000, 7: 321-331; Fassbender et al., *Proc. Natl. Acad. Sci. U.S.A.* 2001, 98: 5856-5861). Given that the brain's cholesterol is synthesized in situ, there is a need for a homeostatic mechanism of reverse transport of cholesterol from the brain to the liver for bile acid production and excretion. The current opinion is that a major pathway for reverse transport involves the enzymatic formation of 24-hydroxycholesterol („cerebrosterol“), its diffusion across cellular membranes and the blood-brain-barrier, and the subsequent transport via circulation to the liver for extraction, modification, and excretion (Dietschy and Turley, *Curr. Opin. Lipidol.* 2001, 12: 105-112). Interestingly, CYP46, the enzyme that catalyses the formation of 24-hydroxycholesterol, is almost exclusively found in brain tissue, thus corroborating the idea of a specialized homeostatic function of this pathway (Lütjohann et al., *Proc. Natl. Acad. Sci. U.S.A.* 1996, 93: 9799-9804; Lund et al., *Proc. Natl. Acad. Sci. U.S.A.* 1999, 96: 7238-7243). In fact, plasma levels of 24-hydroxycholesterol have been suggested as stage markers of neurological diseases including AD (Papassotiropoulos et

al., *NeuroReport* 2000, 11: 1959-62; Bretillon et al., *Neurosci. Lett.* 2000, 293: 87-90; Bogdanovic et al., *Neurosci. Lett.* 2001, 314: 45-48).

The instant invention discloses the differential expression of ABCA1, a member of the large and well investigated family of ATP-binding cassette transporters, in different regions of the AD brain but not in the brains of healthy age-matched control individuals. ABCA1 is a 2261 amino acid protein encoded by the ABCA1 gene on chromosome 9 (Santamarina-Fojo et al., *Proc. Natl. Acad. Sci. U.S.A.* 2000, 97: 7987-7992; GenBank accession number AF275948). ATP-binding cassette transporters make up a family of membrane-embedded transport proteins that utilize the energy of ATP-hydrolysis to accomplish vectorial trans-membrane transport of cargo molecules like ions, metabolites, protein fragments and others. Well-known members of this family are the MDR1, TAP and CFTR transporters, having roles in multidrug resistance, peptide presentation by MHC class I molecules, and cystic fibrosis, respectively (for recent review, Dean et al., *Genome Res.* 2001, 11: 1156-1166).

ABCA1 has been shown to act as an energy-dependent reverse cholesterol and phospholipid transporter in macrophages (for review, Oram and Lawn, *J. Lipid. Res.* 2001, 42: 1173-1179). ABCA1 mRNA was found in the following tissues: liver, intestine, placenta, adipose, adrenal glands, macrophages, and spleen (Langmann et al., *Biochem. Biophys. Res. Comm.* 1999, 257: 29-33; Chawla et al., *Science* 2001, 294: 1866-1870). Mutations in the ABCA1 gene lead to Tangier disease and familial high density lipoprotein deficiency (Brooks-Wilson et al., *Nat. Genet.* 1999, 22: 336-345; Bodzioch et al., *Nat. Genet.* 1999, 22: 347-351; Rust et al., *Nat. Genet.* 1999, 22: 352-355; Oram and Lawn, *J. Lipid. Res.* 2001, 42: 1173-1179). The potential of ABCA1 as a diagnostic marker and therapeutic target for arteriosclerosis, coronary artery disease, cardiovascular diseases and lipid disorders in general has been recognized (WO00/55318, WO00/78971, WO00/78972, WO00/18912, WO01/15676, WO01/70810). However, no mutations in the ABCA1 gene have been found to be associated with a pathological phenotype of said neurodegenerative disorders and to date no experiments have been described that demonstrate a relationship between the dysregulation of ABCA1 gene

expression and the pathology of neurodegenerative diseases, in particular AD. Such a link, as disclosed in the present invention, offers new ways, inter alia, for the diagnosis and treatment of said diseases.

The singular forms "a", "an", and "the" as used herein and in the claims include plural reference unless the context dictates otherwise. For example, "a cell" means as well a plurality of cells, and so forth. The term "and/or" as used in the present specification and in the claims implies that the phrases before and after this term are to be considered either as alternatives or in combination. For instance, the wording "determination of a level and/or an activity" means that either only a level, or only an activity, or both a level and an activity are determined. The term "level" as used herein is meant to comprise a gage of, or a measure of the amount of, or a concentration of a transcription product, for instance an mRNA, or a translation product, for instance a protein or polypeptide. The term "activity" as used herein shall be understood as a measure for the ability of a transcription product or a translation product to produce a biological effect or a measure for a level of biologically active molecules. The term "activity" also refers to enzymatic activity. The terms "level" and/or "activity" as used herein further refer to gene expression levels or gene activity. Gene expression can be defined as the utilization of the information contained in a gene by transcription and translation leading to the production of a gene product. "Dysregulation" shall mean an upregulation or downregulation of gene expression. A gene product comprises either RNA or protein and is the result of expression of a gene. The amount of a gene product can be used to measure how active a gene is. The term "gene" as used in the present specification and in the claims comprises both coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements such as promoters or enhancers, introns, leader and trailer sequences). The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid sequence that does not possess a stop codon in at least one reading frame and therefore can potentially be translated into a sequence of amino acids. "Regulatory elements" shall comprise inducible and

non-inducible promoters, enhancers, operators, and other elements that drive and regulate gene expression. The term "fragment" as used herein is meant to comprise e.g. an alternatively spliced, or truncated, or otherwise cleaved transcription product or translation product. The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically modified, or otherwise altered transcription product, or to a mutant, or chemically modified, or otherwise altered translation product. For instance, a "derivative" may be generated by processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation, or by altered signal peptide cleavage or other types of maturation cleavage. These processes may occur post-translationally. The term "modulator" as used in the present invention and in the claims refers to a molecule capable of changing or altering the level and/or the activity of a gene, or a transcription product of a gene, or a translation product of a gene. Preferably, a "modulator" is capable of changing or altering the biological activity of a transcription product or a translation product of a gene. Said modulation, for instance, may be an increase or a decrease in enzyme activity, a change in binding characteristics, or any other change or alteration in the biological, functional, or immunological properties of said translation product of a gene. The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition or extract that have a positive or negative biological effect on a cell, tissue, body fluid, or within the context of any biological system, or any assay system examined. They can be agonists, antagonists, partial agonists or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic acids, natural or synthetic peptides or protein complexes, or fusion proteins. They may also be antibodies, organic or anorganic molecules or compositions, small molecules, drugs and any combinations of any of said agents above. They may be used for testing, for diagnostic or for therapeutic purposes. The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences which can anneal to a given target polynucleotide by hybridization of the complementary base pairs and can be extended by a polymerase. They may be chosen to be specific to a particular sequence or they may be randomly selected, e.g. they will prime all possible sequences in a mix. The length of primers used herein may vary from

10 nucleotides to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences described and disclosed herein or sequences complementary therewith. They may comprise full length sequences, or fragments, derivatives, isoforms, or variants of a given sequence. The identification of hybridization complexes between a "probe" and an assayed sample allows the detection of the presence of other similar sequences within that sample. As used herein, "homolog or homology" is a term used in the art to describe the relatedness of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which is determined by the degree of identity and/or similarity between said sequences compared. The term "variant" as used herein refers to any polypeptide or protein, in reference to polypeptides and proteins disclosed in the present invention, in which one or more amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus, and/or the C-terminus, and/or within the native amino acid sequences of the native polypeptides or proteins of the present invention. Furthermore, the term "variant" shall include any shorter or longer version of a polypeptide or protein. "Variants" shall also comprise a sequence that has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity with the amino acid sequence of the ABCA1 gene. "Variants" of a protein molecule include, for example, proteins with conservative amino acid substitutions in highly conservative regions. "Proteins and polypeptides" of the present invention include variants, fragments and chemical derivatives of the protein comprising the amino acid sequence of ABCA1. They can include proteins and polypeptides which can be isolated from nature or be produced by recombinant and/or synthetic means. Native proteins or polypeptides refer to naturally-occurring truncated or secreted forms, naturally occurring variant forms (e.g. splice-variants) and naturally occurring allelic variants. The term "isolated" as used herein is considered to refer to molecules that are removed from their natural environment, i.e. isolated from a cell or from a living organism in which they normally occur, and that are separated or essentially purified from the coexisting components with which they are found to be associated in nature. This notion further means that the sequences encoding

such molecules can be linked by the hand of man to polynucleotides, to which they are not linked in their natural state, and that such molecules can be produced by recombinant and/or synthetic means. Even if for said purposes those sequences may be introduced into living or non-living organisms by methods known to those skilled in the art, and even if those sequences are still present in said organisms, they are still considered to be isolated. In the present invention, the terms "risk", "susceptibility", and "predisposition" are tantamount and are used with respect to the probability of developing a neurodegenerative disease, preferably Alzheimer's disease.

The term 'AD' shall mean Alzheimer's disease. "AD-type neuropathology" as used herein refers to neuropathological, neurophysiological, histopathological and clinical hallmarks as described in the instant invention and as commonly known from state-of-the-art literature (see: Iqbal, Swaab, Winblad and Wisniewski, *Alzheimer's Disease and Related Disorders (Etiology, Pathogenesis and Therapeutics)*, Wiley & Sons, New York, Weinheim, Toronto, 1999; Scinto and Daffner, *Early Diagnosis of Alzheimer's Disease*, Humana Press, Totowa, New Jersey, 2000; Mayeux and Christen, *Epidemiology of Alzheimer's Disease: From Gene to Prevention*, Springer Press, Berlin, Heidelberg, New York, 1999; Younkin, Tanzi and Christen, *Presenilins and Alzheimer's Disease*, Springer Press, Berlin, Heidelberg, New York, 1998).

Neurodegenerative diseases or disorders according to the present invention comprise Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain dementia and other tauopathies, and mild-cognitive impairment. Further conditions involving neurodegenerative processes are, for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.

In one aspect, the invention features a method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease. The method comprises: determining a level, or an activity, or both said level and said activity of (i) a transcription product of the ABCA1 gene, and/or of (ii) a translation product of the ABCA1 gene, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject and comparing said level, and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

The invention also relates to the construction and the use of primers and probes which are unique to the nucleic acid sequences, or fragments, or variants thereof, as disclosed in the present invention. The oligonucleotide primers and/or probes can be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive substances. The invention further relates to the detection and the production of said nucleic acid sequences, or fragments and/or variants thereof, using said specific oligonucleotide primers in appropriate combinations. PCR-analysis, a method well known to those skilled in the art, can be performed with said primer combinations to amplify said gene specific nucleic acid sequences from a sample containing nucleic acids. Such sample may be derived either from healthy or diseased subjects. Whether an amplification results in a specific nucleic acid product or not, and whether a fragment of different length can be obtained or not, may be indicative for a neurodegenerative disease, in particular Alzheimer's disease. Thus, the invention provides nucleic acid sequences, oligonucleotide primers, and probes of at least 10 bases in length up to the entire coding and gene sequences, useful for the detection of gene mutations and single nucleotide polymorphisms in a given sample comprising nucleic acid sequences to be examined, which may be associated with neurodegenerative diseases, in

particular Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic tests, preferably also in the format of a kit.

In a further aspect, the invention features a method of monitoring the progression of a neurodegenerative disease in a subject. A level, or an activity, or both said level and said activity, of (i) a transcription product of the ABCA1 gene, and/or of (ii) a translation product of the ABCA1 gene, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject is determined. Said level and/or said activity is compared to a reference value representing a known disease or health status. Thereby the progression of said neurodegenerative disease in said subject is monitored.

In still a further aspect, the invention features a method of evaluating a treatment for a neurodegenerative disease, comprising determining a level, or an activity, or both said level and said activity of (i) a transcription product of the ABCA1 gene, and/or of (ii) a translation product of the ABCA1 gene, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample obtained from a subject being treated for said disease. Said level, or said activity, or both said level and said activity are compared to a reference value representing a known disease or health status, thereby evaluating the treatment for said neurodegenerative disease.

In a preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said gene coding for ABCA1 is the gene coding for the human ATP-binding cassette transporter A1 (ABCA1), also termed ATP-binding cassette 1, ABC transporter 1 (ABC-1) or cholesterol efflux regulatory protein (CERP), represented by SEQ ID NO. 1 (Genbank accession number O95477; mRNA GenBank accession number AF285167, said mRNA sequence of AF285167 has been corrected according to GenBank accession number AF275948 and ESTs from the GenBank database).

In a further preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said neurodegenerative disease or disorder is Alzheimer's disease, and said subjects suffer from Alzheimer's disease.

The present invention discloses the detection and differential expression and regulation of the ABCA1 gene in specific brain regions of AD patients. Consequently, the ABCA1 gene and its corresponding transcription and/or translation products may have a causative role in the regional selective neuronal degeneration typically observed in AD. Alternatively, ABCA1 may confer a neuroprotective function to the remaining surviving nerve cells. Based on these disclosures, the present invention has utility for the diagnostic evaluation and prognosis as well as for the identification of a predisposition to a neurodegenerative disease, in particular AD. Furthermore, the present invention provides methods for the diagnostic monitoring of patients undergoing treatment for such a disease.

It is particularly preferred that said sample to be analyzed and determined is selected from the group comprising brain tissue, or other tissues, organs, or body cells. The sample can also comprise cerebrospinal fluid or other body fluids including saliva, urine, blood, serum plasma, or mucus. Preferably, the methods of diagnosis, prognosis, monitoring the progression or evaluating a treatment for a neurodegenerative disease, according to the instant invention, can be practiced *ex corpore*, and such methods preferably relate to samples, for instance, body fluids or cells, removed, collected, or isolated from a subject or patient.

In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity of (i) a transcription product of the ABCA1 gene, and/or of (ii) a translation product of the ABCA1 gene, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from a subject not suffering from said neurodegenerative disease.

In preferred embodiments, an alteration in the level and/or activity of a transcription product of the ABCA1 gene and/or of a translation product of the ABCA1 gene and/or of a fragment, or derivative, or variant thereof, in a sample cell, or tissue, or body fluid from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a neurodegenerative disease, particularly AD.

In preferred embodiments, measurement of the level of transcription products of the ABCA1 gene is performed in a sample from a subject using a quantitative PCR-analysis with primer combinations to amplify said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted from a sample of a subject. A Northern blot with probes specific for said gene can also be applied. It might further be preferred to measure transcription products by means of chip-based micro-array technologies. These techniques are known to those of ordinary skill in the art (see Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001; Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000). An example of an immunoassay is the detection and measurement of enzyme activity as disclosed and described in the patent application WO 02/14543.

Furthermore, a level and/or an activity of a translation product of the ABCA1 gene and/or of a fragment, or derivative, or variant of said translation product, and/or the level of activity of said translation product, and/or of a fragment, or derivative, or variant thereof, can be detected using an immunoassay, an activity assay, and/or a binding assay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody by the use of enzymatic, chromodynamic, radioactive, magnetic, or luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs,

Western blots, and other techniques known to those of ordinary skill in the art (see Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R, *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford; England, 1999). All these detection techniques may also be employed in the format of microarrays, protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip based technologies (see Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000).

In a preferred embodiment, the level, or the activity, or both said level and said activity of (i) a transcription product of the ABCA1 gene, and/or of (ii) a translation product of the ABCA1 gene, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a series of samples taken from said subject over a period of time is compared, in order to monitor the progression of said disease. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings. In yet another preferred embodiment, said level and/or activity is determined before and after said treatment of said subject.

In another aspect, the invention features a kit for diagnosing or prognosticating neurodegenerative diseases, in particular AD, in a subject, or determining the propensity or predisposition of a subject to develop a neurodegenerative disease, in particular AD, said kit comprising:

(a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of the ABCA1 gene (ii) reagents that selectively detect a translation product of the ABCA1 gene; and
(b) an instruction for diagnosing or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of a subject to develop such a disease by

- detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of the ABCA1 gene, in a sample from said subject; and

- diagnosing or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of said subject to develop such a disease,

wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status, indicates a diagnosis or prognosis of a neurodegenerative disease, in particular AD, or an increased propensity or predisposition of developing such a disease. The kit, according to the present invention, may be particularly useful for the identification of individuals that are at risk of developing a neurodegenerative disease, in particular AD. Consequently, the kit, according to the invention, may serve as a means for targeting identified individuals for early preventive measures or therapeutic intervention prior to disease onset, before irreversible damage in the course of the disease has been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention is useful for monitoring a progression of a neurodegenerative disease, in particular AD, in a subject, as well as monitoring success or failure of therapeutic treatment for such a disease of said subject.

In another aspect, the invention features a method of treating or preventing a neurodegenerative disease, in particular AD, in a subject comprising the administration to said subject in a therapeutically or prophylactically effective amount of an agent or agents which directly or indirectly affect a level, or an activity, or both said level and said activity, of (i) the ABCA1 gene, and/or (ii) a transcription product of the ABCA1 gene, and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). Said agent may comprise a small molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said peptide, oligopeptide, or polypeptide may comprise an amino acid sequence of a translation product of a gene coding for ABCA1, or a fragment, or derivative, or a variant thereof. An agent for treating or preventing a neurodegenerative disease, in particular AD,

according to the instant invention, may also consist of a nucleotide, an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may comprise a nucleotide sequence of the gene coding for ABCA1, either in sense orientation or in antisense orientation.

In preferred embodiments, the method comprises the application of per se known methods of gene therapy and/or antisense nucleic acid technology to administer said agent or agents. In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein, and modulation of endogenous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, *Acc Chem Res* 1993, 26: 274-278 and Mulligan, *Science* 1993, 260: 926-931) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane perturbation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, *Curr Opin Neurobiol* 1993, 3: 743-748).

In particular, the invention features a method of treating or preventing a neurodegenerative disease by means of antisense nucleic acid therapy, i.e. the down-regulation of an inappropriately expressed or defective gene by the introduction of antisense nucleic acids or derivatives thereof into certain critical cells (see e.g. Gillespie, *DN&P* 1992, 5: 389-395; Agrawal and Akhtar, *Trends Biotechnol* 1995, 13: 197-199; Crooke, *Biotechnology* 1992, 10: 882-6). Apart from hybridization strategies, the application of ribozymes, i.e. RNA molecules that act as enzymes, destroying RNA that carries the message of disease has also been described (see e.g. Barinaga, *Science* 1993, 262: 1512-1514). In preferred embodiments, the subject to be treated is a human, and therapeutic antisense nucleic acids or derivatives thereof are directed

against transcripts of a gene coding for ABCA1. It is preferred that cells of the central nervous system, preferably the brain, of a subject are treated in such a way. Cell penetration can be performed by known strategies such as coupling of antisense nucleic acids and derivatives thereof to carrier particles, or the above described techniques. Strategies for administering targeted therapeutic oligodeoxynucleotides are known to those of skill in the art (see e.g. Wickstrom, *Trends Biotechnol* 1992, 10: 281-287). In some cases, delivery can be performed by mere topical application. Further approaches are directed to intracellular expression of antisense RNA. In this strategy, cells are transformed *ex vivo* with a recombinant gene that directs the synthesis of an RNA that is complementary to a region of target nucleic acid. Therapeutical use of intracellularly expressed antisense RNA is procedurally similar to gene therapy. A recently developed method of regulating the intracellular expression of genes by the use of double-stranded RNA, known variously as RNA interference (RNAi), can be another effective approach for nucleic acid therapy (Hannon, *Nature* 2002, 418: 244-251).

In further preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically mediated transfection, in particular calcium phosphate transfection or liposomal mediated transfection (see McClland and Pardee, *Expression Genetics: Accelerated and High-Throughput Methods*, Eaton Publishing, Natick, MA, 1999).

In preferred embodiments, said agent for treating and preventing a neurodegenerative disease, in particular AD, is a therapeutic protein which can be administered to said subject, preferably a human, by a process

comprising introducing subject cells into said subject, said subject cells having been treated *in vitro* to insert a DNA segment encoding said therapeutic protein, said subject cells expressing *in vivo* in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells *in vitro* by a viral vector, in particular a retroviral vector.

Methods of treatment, according to the present invention, comprise the application of therapeutic cloning, transplantation, and stem cell therapy using embryonic stem cells or embryonic germ cells and neuronal adult stem cells, combined with any of the previously described cell- and gene therapeutic methods. Stem cells may be totipotent or pluripotent. They may also be organ-specific. Strategies for repairing diseased and/or damaged brain cells or tissue comprise (i) taking donor cells from an adult tissue. Nuclei of those cells are transplanted into unfertilized egg cells from which the genetic material has been removed. Embryonic stem cells are isolated from the blastocyst stage of the cells which underwent somatic cell nuclear transfer. Use of differentiation factors then leads to a directed development of the stem cells to specialized cell types, preferably neuronal cells (Lanza et al., *Nature Medicine* 1999, 9: 975-977), or (ii) purifying adult stem cells, isolated from the central nervous system, or from bone marrow (mesenchymal stem cells), for *in vitro* expansion and subsequent grafting and transplantation, or (iii) directly inducing endogenous neural stem cells to proliferate, migrate, and differentiate into functional neurons (Peterson DA, *Curr. Opin. Pharmacol.* 2002, 2: 34-42). Adult neural stem cells are of great potential for repairing damaged or diseased brain tissues, as the germinal centers of the adult brain are free of neuronal damage or dysfunction (Colman A, *Drug Discovery World* 2001, 7: 66-71).

In preferred embodiments, the subject for treatment or prevention, according to the present invention, can be a human, an experimental animal, e.g. a mouse or a rat, a domestic animal, or a non-human primate. The experimental

animal can be an animal model for a neurodegenerative disorder, e.g. a transgenic mouse and/or a knock-out mouse with an AD-type neuropathology.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) the ABCA1 gene, and/or (ii) a transcription product of the ABCA1 gene and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

In an additional aspect, the invention features a pharmaceutical composition comprising said modulator and preferably a pharmaceutical carrier. Said carrier refers to a diluent, adjuvant, excipient, or vehicle with which the modulator is administered.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) the ABCA1 gene, and/or (ii) a transcription product of the ABCA1 gene, and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for use in a pharmaceutical composition.

In another aspect, the invention provides for the use of a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) the ABCA1 gene, and/or (ii) a transcription product of the ABCA1 gene and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular AD.

In one aspect, the present invention also provides a kit comprising one or more containers filled with a therapeutically or prophylactically effective amount of said pharmaceutical composition.

In a further aspect, the invention features a recombinant, non-human animal comprising a non-native gene sequence coding for ABCA1, or a fragment, or a derivative, or a variant thereof. The generation of said recombinant, non-human animal comprises (i) providing a gene targeting construct containing said gene sequence and a selectable marker sequence, and (ii) introducing said targeting construct into a stem cell of a non-human animal, and (iii) introducing said non-human animal stem cell into a non-human embryo, and (iv) transplanting said embryo into a pseudopregnant non-human animal, and (v) allowing said embryo to develop to term, and (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said gene is mis-expressed, or under-expressed, or over-expressed, and wherein said disruption or alteration results in said non-human animal exhibiting a predisposition to developing symptoms of neuropathology similar to a neurodegenerative disease, in particular AD. Strategies and techniques for the generation and construction of such an animal are known to those of ordinary skill in the art (see e.g. Capecchi, *Science* 1989, 244: 1288-1292 and Hogan et al., 1994, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York and Jackson and Abbott, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press, Oxford, England, 1999). It is preferred to make use of such a recombinant non-human animal as an animal model for investigating neurodegenerative diseases, in particular Alzheimer's disease. Such an animal may be useful for screening, testing and validating compounds, agents and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

In another aspect, the invention features an assay for screening for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) the ABCA1 gene, and/or (ii) a transcription product of the

ABCA1 gene, and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). This screening method comprises (a) contacting a cell with a test compound, and (b) measuring the activity, or the level, or both the activity and the level of one or more substances recited in (i) to (iv), and (c) measuring the activity, or the level, or both the activity and the level of said substances in a control cell not contacted with said test compound, and (d) comparing the levels of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of said substances in the contacted cells indicates that the test compound is a modulator of said diseases and disorders.

In one further aspect, the invention features a screening assay for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) the ABCA1 gene, and/or (ii) a transcription product of the ABCA1 gene, and/or (iii) a translation product of the ABCA1 gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii), comprising (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders, and (b) measuring the activity and/or level of one or more substances recited in (i) to (iv), and (c) measuring the activity and/or level of said substances in a matched control animal which is equally predisposed to developing or has already developed symptoms of said diseases and to which animal no such test compound has been administered, and (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases and disorders.

In a preferred embodiment, said test animal and/or said control animal is a recombinant, non-human animal which expresses a gene coding for ABCA1, or a fragment, or a derivative, or a variant thereof, under the control of a

transcriptional regulatory element which is not the native ABCA1 gene transcriptional control regulatory element.

In another embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases by a method of the aforementioned screening assays and (ii) admixing the modulator with a pharmaceutical carrier. However, said modulator may also be identifiable by other types of screening assays.

In another aspect, the present invention provides for an assay for testing a compound, preferably for screening a plurality of compounds, for inhibition of binding between a ligand and a translation product of the gene coding for ABCA1, or a fragment, or derivative, or variant thereof. Said screening assay comprises the steps of (i) adding a liquid suspension of said ABCA1 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers, and (iii) adding a detectable, preferably a fluorescently labeled ligand to said containers, and (iv) incubating said ABCA1 translation product, or said fragment, or derivative, or variant thereof, and said compound or plurality of compounds, and said detectable, preferably fluorescently labeled ligand, and (v) measuring the amounts of fluorescence associated with said ABCA1 translation product, or with said fragment, or derivative, or variant thereof, and (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said ABCA1 translation product, or said fragment, or derivative, or variant thereof. It might be preferred to reconstitute said ABCA1 translation product, or fragment, or derivative, or variant thereof, into artificial liposomes to generate the corresponding proteoliposomes to determine the inhibition of binding between a ligand and said ABCA1 translation product. Methods of reconstitution of ATP binding cassette transporters from detergent into liposomes are known to those skilled in the art (Hagmann et al., Eur. J. Biochem. 1999, 265: 281-289; Ahn

et al., J. Biol. Chem. 2000, 275: 20399-20405). Instead of utilizing a fluorescently labeled ligand, it might in some aspects be preferred to use any other detectable label known to the person skilled in the art, e.g. radioactive labels, and detect it accordingly. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to inhibit the binding of a ligand to an ABCA1 translation product, or a fragment, or derivative, or variant thereof. One example of a fluorescent binding assay, in this case based on the use of carrier particles, is disclosed and described in patent application WO 00/52451. A further example is the competitive assay method as described in patent WO 02/01226. Preferred signal detection methods for screening assays of the instant invention are described in the following patent applications: WO 96/13744, WO 98/16814, WO 98/23942, WO 99/17086, WO 99/34195, WO 00/66985, WO 01/59436, WO 01/59416.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a gene product of the gene coding for ABCA1 by the aforementioned inhibitory binding assay and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another aspect, the invention features an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to a translation product of the gene coding for ABCA1, or to a fragment, or derivative, or variant thereof. Said screening assay comprises (i) adding a liquid suspension of said ABCA1 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a fluorescently labeled compound or a plurality of fluorescently labeled compounds to be screened for said binding to said plurality of containers, and (iii) incubating said ABCA1 translation product, or said fragment, or derivative, or variant thereof, and said fluorescently labeled compound or fluorescently labeled compounds, and (iv) measuring the

amounts of fluorescence associated with said ABCA1 translation product, or with said fragment, or derivative, or variant thereof, and (v) determining the degree of binding by one or more of said compounds to said ABCA1 translation product, or said fragment, or derivative, or variant thereof. In this type of assay it might be preferred to use a fluorescent label. However, any other type of detectable label might also be employed. Also in this type of assay it might be preferred to reconstitute an ABCA1 translation product or fragment, or derivative, or variant thereof into artificial liposomes as described in the present invention. Said assay methods may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to bind to an ABCA1 translation product, or fragment, or derivative, or variant thereof.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a gene product of the ABCA1 gene by the aforementioned binding assays and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another embodiment, the present invention provides for a medicament obtainable by any of the methods according to the herein claimed screening assays. In one further embodiment, the instant invention provides for a medicament obtained by any of the methods according to the herein claimed screening assays.

The present invention features a protein molecule shown in SEQ ID NO. 1, said protein molecule being a translation product of the gene coding for the ATP-binding cassette transporter ABCA1 protein, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

The present invention further features a protein molecule shown in SEQ ID NO. 1, said protein molecule being a translation product of the gene coding for the ATP-binding cassette transporter ABCA1 protein, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

The present invention features an antibody which is specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID. NO. 1, or a fragment, or derivative, or variant thereof. The immunogen may comprise immunogenic or antigenic epitopes or portions of SEQ ID. NO. 1, wherein said immunogenic or antigenic portion is a polypeptide, and wherein said polypeptide elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically bound by said antibody. Methods for generating antibodies are well known in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988). The term "antibody", as employed in the present invention, encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof (see Dubel and Breitling, *Recombinant Antibodies*, Wiley-Liss, New York, NY, 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic and therapeutic methods, based on state-in-the-art techniques (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R., *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford, England, 1999) such as enzyme-immuno assays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmuno assays, chemoluminescence-immuno assays, Western-blot, immunoprecipitation and antibody microarrays. These methods involve the detection of translation products of the ABCA1 gene, or fragments, or derivatives, or variants thereof.

In a preferred embodiment of the present invention, said antibodies can be used for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell. Preferably, the pathological state relates to a neurodegenerative disease, in particular to AD. Immunocytochemical staining of a cell can be carried out by a number of different experimental methods well known in the art. It might be preferred, however, to apply an automated method for the detection of antibody binding, wherein the determination of the degree of staining of a cell, or the determination of the cellular or subcellular staining pattern of a cell, or the topological distribution of an antigen on the cell surface or among organelles and other subcellular structures within the cell, are carried out according to the method described in US patent 6150173.

Other features and advantages of the invention will be apparent from the following description of figures and examples which are illustrative only and not intended to limit the remainder of the disclosure in any way.

Figure 1 depicts the brain regions with selective vulnerability to neuronal loss and degeneration in AD. Primarily, neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus, and the amygdala are subject to degenerative processes in AD (Terry et al., *Annals of Neurology* 1981, 10:184-192). These brain regions are mostly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex, and the cerebellum remain largely intact and preserved from neurodegenerative processes in AD. Brain tissues from the frontal cortex (F), the temporal cortex (T) and the hippocampus (H) of AD patients and healthy, age-matched control individuals were used for the herein disclosed examples. For illustrative purposes, the image of a normal healthy brain was taken from a publication by Strange (*Brain Biochemistry and Brain Disorders*, Oxford University Press, Oxford, 1992, p.4).

Figures 2 and 3 demonstrate the differential expression of the ABCA1 gene in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (Figure 2a) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (Figure 3a) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (Figure 2b for frontal cortex and temporal cortex, Figure 3b for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figures depict the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of the ABCA1 cDNAs from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (Figures 2b and 3b, arrowheads), whereas in Alzheimer's disease (Figures 2a and 3a, arrowheads) there is a significant separation of the corresponding curves, indicating a differential expression of the gene coding for ABCA1 in the respective analyzed brain regions.

Figure 4 charts the schematic alignment of the herein used RT-PCR primer sequences to the nucleotide sequence of the human ABCA1 gene (GenBank accession number AF285167, said sequence of AF285167 being corrected according to GenBank accession number AF275948 and corresponding ESTs from the GenBank database). For illustrating purposes, only exon 1 and exon 50 are sketched; polyA: polyadenylation site; primers are indicated by arrows and positional numbering.

Figure 5 outlines the exact nucleotide sequence alignment of the ABCA1 primer pair to the nucleotide sequence of the human ABCA1 gene (GenBank accession number AF285167, said sequence of AF285167 being corrected according to GenBank accession number AF275948 and corresponding ESTs from the GenBank database).

Figure 6 discloses SEQ ID NO. 1, the polypeptide sequence of human ABCA1, comprising 2261 amino acids (GenBank accession number O95477).

Figure 7 depicts human cerebral cortex double-labeled with anti-ABCA1 rabbit (red signals) and anti-ABCA1 goat (green signals) polyclonal antibodies. Immunoreactivity of ABCA1 was detected in both the pre-central cortex (CT) and in the white matter (WM) (Figure 7a, low magnification). In the cortex, ABCA1 immunoreactivity was observed in neuronal and glial cell bodies, as well as in endothelial cells. ABCA1 immunoreactivity was found to be present in the cytoplasm and associated with plasma membranes (Figure 7b, high magnification). Both antibodies used showed highly overlapping signals, suggesting overlapping immuno-specificities. Blue signals indicate nuclei stained with DAPI.

Table 1 lists the gene expression levels in the temporal cortex relative to the frontal cortex for the ABCA1 gene in seven Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (1.18 to 2.99 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.81 to 1.49 fold). The scatter diagram visualizes individual values of the temporal to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles), respectively.

Table 2 lists the ABCA1 gene expression levels in the hippocampus relative to the frontal cortex in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (1.96 to 5.83 fold) and three healthy, age-matched control individuals, herein identified

by internal reference numbers C004, C005, C008 (1.18 to 3.22 fold). The scatter diagram visualizes individual values of the hippocampus to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles), respectively.

EXAMPLE I:

(i) Brain tissue dissection from patients with AD:

Brain tissues from AD patients and age-matched control subjects were collected within 6 hours post-mortem and immediately frozen on dry ice. Sample sections from each tissue were fixed in paraformaldehyde for histopathological confirmation of the diagnosis. Brain areas for differential expression analysis were identified (see Figure 1) and stored at -80°C until RNA extractions were performed.

(ii) Isolation of total mRNA:

Total RNA was extracted from post-mortem brain tissue by using the RNeasy kit (Qiagen) according to the manufacturer's protocol. The accurate RNA concentration and the RNA quality were determined with the DNA LabChip system using the Agilent 2100 Bioanalyzer (Agilent Technologies). For additional quality testing of the prepared RNA, i.e. exclusion of partial degradation and testing for DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic DNA as reference control were used to generate a melting curve with the LightCycler technology as described in the manufacturer's protocol (Roche).

(iii) Quantitative RT-PCR analysis:

The expression levels of the human ABCA1 gene in temporal cortex versus frontal cortex were analyzed using the LightCycler technology (Roche). This technique features rapid thermal cycling for the polymerase chain reaction as well as real-time measurement of fluorescent signals during amplification and therefore allows for highly accurate quantification of RT-PCR products by

using a kinetic, rather than an endpoint readout. The ratios of ABCA1 cDNA from the temporal cortex and frontal cortex, and from the hippocampus and frontal cortex, respectively were determined (relative quantification).

First, a standard curve was generated to determine the efficiency of the PCR with specific primers for the gene coding for human ABCA1:

5'-TGTTGCATCCCCCTTAGAATGT-3' and

5'-GAGGGCCAATGATGAACAAAG-3'.

PCR amplification (95 °C and 1 sec, 56 °C and 5 sec, and 72 °C and 5 sec) was performed in a volume of 20 µl containing LightCycler-FastStart DNA Master SYBR Green I mix (contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead of dTTP, SYBR Green I dye, and 1 mM MgCl₂; Roche), 0.5 µM primers, 2 µl of a cDNA dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain cDNA; Clontech) and, depending on the primers used, additional 3 mM MgCl₂. Melting curve analysis revealed a single peak at approximately 79°C with no visible primer dimers. Quality and size of the PCR product were determined with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies). A single peak at the expected size of 114 bp for ABCA1 was observed in the electropherogram of the sample.

In an analogous manner, the PCR protocol was applied to determine the PCR efficiency of a set of reference genes which were selected as a reference standard for quantification. In the present invention, the mean value of five such reference genes was determined: (1) cyclophilin B, using the specific primers 5'-ACTGAAGCACTACGGGCCTG-3' and 5'-AGCCGTTGGTGTCTT-TGCC-3' except for MgCl₂ (an additional 1 mM was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 87 °C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band of the expected size (62 bp). (2) Ribosomal protein S9 (RPS9), using the specific primers 5'-GGTCAAATTTACCCTGGCCA-3' and 5'-TCTCATCAAGCGTCAGCAGTTC-3' (exception: additional 1 mM MgCl₂ was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 85°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (62 bp). (3)

beta-actin, using the specific primers 5'-TGGAACGGTGAAGGTGACA-3' and 5'-GGCAAGGGACTTCCTGTAA-3'. Melting curve analysis revealed a single peak at approximately 87°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (142 bp). (4) GAPDH, using the specific primers 5'-CGTCATGGGTGTGAACCATG-3' and 5'-GCTAAGCAGTTGGTGGTGCAG-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (81 bp). (5) Transferrin receptor TRR, using the specific primers 5'-GTCGCTGGTCAGTTCGTGATT-3' and 5'-AGCAGTTGGCTGTTGTACCTCTC-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (80 bp).

For calculation of the values, first the logarithm of the cDNA concentration was plotted against the threshold cycle number C_t for the gene coding for ABCA1 and the five reference standard genes. The slopes and the intercepts of the standard curves (i.e. linear regressions) were calculated for all genes. In a second step, cDNAs from temporal cortex and frontal cortex, and from hippocampus and frontal cortex, respectively, were analyzed in parallel and normalized to cyclophilin B. The C_t values were measured and converted to ng total brain cDNA using the corresponding standard curves:

$$10^{((C_t \text{ value} - \text{intercept}) / \text{slope})} \quad [\text{ng total brain cDNA}]$$

The values for frontal and temporal cortex cDNAs of ABCA1, and the values for hippocampus and frontal cortex ABCA1 cDNAs, respectively, were normalized to cyclophilin B, and the ratios were calculated according to formulas:

$$\text{Ratio} = \frac{\text{ABCA1 temporal [ng]} / \text{cyclophilin B temporal [ng]}}{\text{ABCA1 frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

$$\text{Ratio} = \frac{\text{ABCA1 hippocampus [ng]} / \text{cyclophilin B hippocampus [ng]}}{\text{ABCA1 frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

In a third step, the set of reference standard genes was analyzed in parallel to determine the mean average value of the temporal to frontal ratios, and of the hippocampal to frontal ratios, respectively, of expression levels of the reference standard genes for each individual brain sample. As cyclophilin B was analyzed in step 2 and step 3, and the ratio from one gene to another gene remained constant in different runs, it was possible to normalize the values for ABCA1 to the mean average value of the set of reference standard genes instead of normalizing to one single gene alone. The calculation was performed by dividing the respective ratio shown above by the deviation of cyclophilin B from the mean value of all housekeeping genes. The results of such quantitative RT-PCR analysis for the ABCA1 gene are shown in Figure 2 and Figure 3.

(iv) Immunohistochemistry:

For immunofluorescence staining of ABCA1 in human brain, frozen sections were prepared from post-mortem pre-central gyrus of a donor person (Cryostat Leica CM3050S) and fixed in acetone for 10 min. After washing in PBS, the sections were pre-incubated with blocking buffer (10% normal goat serum, 0.2% Triton X-100 in PBS) for 30min, and then incubated with both anti-ABCA1 rabbit polyclonal antibodies (1:50 diluted in blocking buffer; Abcam, Bad Nauheim) and anti-ABCA1 goat polyclonal antibodies (N-15, 1:20 diluted in blocking buffer; Santa Cruz Biotechnology, Heidelberg) overnight at 4°C. After rinsing three times in 0.1% Triton X-100/PBS, the sections were

incubated with Cy3-conjugated donkey anti-rabbit IgG (1:600 diluted in 1% BSA/PBS) and FITC-conjugated donkey anti-goat IgG (1:150 diluted in 1% BSA/PBS) for 2 hours at room temperature, and then again washed in PBS. Staining of the nuclei was performed by incubation of the sections with 5 μ M DAPI in PBS for 3min (blue signal). In order to block the autofluorescence of lipofuscin in human brain, the sections were treated with 1% Sudan Black B in 70% ethanol for 2-10 min at room temperature, sequentially dipped in 70% ethanol, distilled water and PBS. The sections were coverslipped by 'Vectrashield mounting medium' (Vector Laboratories, Burlingame, CA) and observed under an inverted microscope (IX81, Olympus Optical). The digital images were captured with the appropriate software (AnalySiS, Olympus Optical).

CLAIMS

1. A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising:

determining a level and/or an activity of

- (i) a transcription product of the ABCA1 gene, and/or
- (ii) a translation product of the ABCA1 gene, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

2. A method of monitoring the progression of a neurodegenerative disease in a subject, comprising:

determining a level and/or an activity of

- (i) a transcription product of the ABCA1 gene, and/or
- (ii) a translation product of the ABCA1 gene, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby monitoring the progression of said neurodegenerative disease in said subject.

3. A method of evaluating a treatment for a neurodegenerative disease, comprising:

determining a level and/or an activity of

- (i) a transcription product of the ABCA1 gene, and/or
- (ii) a translation product of the ABCA1 gene, and/or

(iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from a subject being treated for said disease and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby evaluating said treatment for said neurodegenerative disease.

4. The method according to any of claims 1 to 3 wherein said neurodegenerative disease is Alzheimer's disease.

5. The method according to any of claims 1 to 4 wherein said sample comprises a cell, or a tissue, or a body fluid, in particular cerebrospinal fluid or blood.

6. The method according to any of claims 1 to 5 wherein said reference value is that of a level and/or an activity of

- (i) a transcription product of the ABCA1 gene, and/or
- (ii) a translation product of the ABCA1 gene, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from a subject not suffering from said neurodegenerative disease.

7. The method according to any of claims 1 to 6 wherein an alteration in the level and/or activity of a transcription product of the gene coding for ABCA1 and/or a translation product of the gene coding for ABCA1 and/or a fragment, or derivative, or variant thereof, in a sample cell, or tissue, or body fluid, in particular cerebrospinal fluid, from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

8. A kit for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop such a disease, said kit comprising:

- (a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of the ABCA1 gene and (ii) reagents that selectively detect a translation product of the ABCA1 gene; and
- (b) an instruction for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by (i) detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of the ABCA1 gene, in a sample from said subject; and (ii) diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease, wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease.

9. A method of treating or preventing a neurodegenerative disease, in particular Alzheimer's disease, in a subject comprising administering to said subject in a therapeutically or prophylactically effective amount an agent or agents which directly or indirectly affect an activity and/or a level of

- (i) the ABCA1 gene, and/or
- (ii) a transcription product of the ABCA1 gene, and/or
- (iii) a translation product of the ABCA1 gene, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii).

10. A modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of

- (i) the ABCA1 gene, and/or
- (ii) a transcription product of the ABCA1 gene, and/or
- (iii) a translation product of the ABCA1 gene, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii).

11. A recombinant, non-human animal comprising a non-native gene sequence coding for ABCA1 or a fragment, or a derivative, or a variant thereof, said animal being obtainable by:

- (i) providing a gene targeting construct comprising said gene sequence and a selectable marker sequence, and
- (ii) introducing said targeting construct into a stem cell of a non-human animal, and
- (iii) introducing said non-human animal stem cell into a non-human embryo, and
- (iv) transplanting said embryo into a pseudopregnant non-human animal, and
- (v) allowing said embryo to develop to term, and
- (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and
- (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said disruption results in said non-human animal exhibiting a predisposition to developing symptoms of a neurodegenerative disease or related diseases or disorders.

12. Use of the recombinant, non-human animal according to claim 11 for screening, testing, and validating compounds, agents, and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

13. An assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

- (i) the ABCA1 gene, and/or
- (ii) a transcription product of the ABCA1 gene, and/or
- (iii) a translation product of the ABCA1 gene, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

- (a) contacting a cell with a test compound;
- (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);
- (c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and
- (d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.

14. A method of screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

- (i) the ABCA1 gene, and/or
- (ii) a transcription product of the ABCA1 gene, and/or
- (iii) a translation product of the ABCA1 gene, and/or
- (v) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

- (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect of the substances recited in (i) to (iv);
- (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

- (c) measuring the activity and/or level of one or more substances recited in (i) or (iv) in a matched control animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect to the substances recited in (i) to (iv) and to which animal no such test compound has been administered;
- (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases or disorders.

15. The method according to claim 14 wherein said test animal and/or said control animal is a recombinant animal which expresses a gene coding for ABCA1, or a fragment, or a derivative, or a variant thereof, under the control of a transcriptional control element which is not the native ABCA1 gene transcriptional control element.

16. An assay for testing a compound, preferably for screening a plurality of compounds for inhibition of binding between a ligand and an ABCA1 translation product, or a fragment, or derivative, or variant thereof, said assay comprising the steps of:

- (i) adding a liquid suspension of said ABCA1 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers;
- (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers;
- (iii) adding a detectable ligand, preferably a fluorescently labeled ligand to said containers;
- (iv) incubating said ABCA1 translation product, or said fragment, or derivative, or variant thereof, and said compound or compounds, and said detectable, preferably said fluorescently labeled ligand;
- (v) measuring amounts of detectable ligand or fluorescence associated with said ABCA1 translation product, or with said fragment, or derivative, or variant thereof; and

- (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said ABCA1 translation product, or said fragment, or derivative, or variant thereof.

17. An assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to an ABCA1 translation product, or to a fragment, or derivative, or variant thereof, said assay comprising the steps of:


- (i) adding a liquid suspension of said ABCA1 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers;
- (ii) adding a detectable compound, preferably a plurality of detectable compounds, in particular a fluorescently labeled compound or a plurality of fluorescently labeled compounds to be screened for said binding to said plurality of containers;
- (iii) incubating said ABCA1 translation product, or said fragment, or derivative, or variant thereof, and said detectable, preferably said fluorescently labeled compound or fluorescently labeled compounds;
- (iv) measuring amounts of detectable compound or fluorescence associated with said ABCA1 translation product, or with said fragment, or derivative, or variant thereof; and
- (v) determining the degree of binding by one or more of said compounds to said ABCA1 translation product, or said fragment, or derivative, or variant thereof.

18. A protein molecule shown in SEQ ID NO. 1, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.


19. A protein molecule shown in SEQ ID NO. 1, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

20. Use of an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 1, or a fragment, or derivative, or variant thereof, for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell.

**Figure 1: Identification of genes involved in
Alzheimer's Disease pathology**



**Figure 2: Differential expression of ABCA1 as determined by
RT-PCR analysis**



**Figure 3: Differential expression of ABCA1 as determined by
RT-PCR analysis**




Figure 4: Schematic alignment of ABCA1 RT-PCR primers with human ABCA1 cDNA (GenBank accession number: AF285167)



**Figure 5: Alignment of ABCA1 RT-PCR primers
with ABCA1 cDNA (GenBank
accession number AF285167)**

```
      1 TGTTCATCCCCCTTAGAATGT 22
        |||||
10031 TGTTCATCCCCCTTAGAATGT 10052
```

```
      21 CTTTGTTTCATCATTGGCCCTC 1
        |||||
10124 CTTTGTTTCATCATTGGCCCTC 10144
```

Figure 6: SEQ ID NO.1: amino acid sequence of human ABCA1

Length: 2261 aa

```

1  MACWPQLRLL LWKNLTFRRR QTCQLLLEVA WPLFIFLILI SVRLSYPPYE
51  QHECHFPNKA MPSAGTLPWV QGIICNANNP CRYPTOGEA PGVVGNFNKS
101  IVARLFSDAR RLLYSQKDT SMKDMRKVLR TLQQIKKSSS NLKLQDFLVD
151  NETFSGFLYH NLSLPKSTVD KMLRADVILH KVFLQGYQLH LTSLCNGSKS
201  EEMIQLGDQE VSELCGLPRE KLAAAEVRLR SNMDILKPIL RTLNSTSPFP
251  SKELAEATKT LLHSLGTLAQ ELFSMRSWSD MRQEVMTLTN VNSSSSSTQI
301  YQAVSRIVCG HPEGGLKIK SLNWEEDNNY KALFGGNGTE EDAETFYDNS
351  TTPYCNDLMK NLESSPLSRI IWKALKPLLV GKILYTPDTP ATRQVMAEVN
401  KTFQELAVFH DLEGMWHEELS PKIWTFMENS QEMDLVRMLL DSRDNDHFWE
451  QQLDGLDWTQ QDIVAFLAKH PEDVQSSNGS VYTWREAFNE TNQAIRTISR
501  FMECVNLNKL EPIATEVWLI NKSMEILLDER KFWAGIVFTG ITPGSIELPH
551  HVKYKIRMDI DNVERTNKIK DGYWDPGPRA DPFEDMRYVW GGFAYLQDVV
601  EQAIIRVLTG TEKKTGVYMQ QMPYPCYVDD IFLRVMSRSM PLFMTLAWIY
651  SVAVIKGIY YEKEARLKET MRIMGLDNSI LWFSWFISL IPLLVSAGLL
701  VVILKLGNNL PYSDPSVVFV FLSVFAVVTI LQCFLISTLF SRANLAAACG
751  GIIYFTLYLP YVLCVAWQDY VGFTLKIFAS LLSPVAFGFG CEYFALFEEQ
801  GIGVQWDNLF ESPVEEDGFN LTTSVSMMLF DTFLYGVMTW YIEAVFPGQY
851  GIPRPWYFPC TKSYPWFGEES DEKSHPGSNQ KRISEICMEE EPTHLKLGVS
901  IQNLVKVYRD GMKVAVDGLA LNFYEGQITS FLGHNGAGKT TTMSILTGLF
951  PPTSGTAYIL GKDIRSEMST IRQNLGVCQP HNVLFDMLTV EEHIWFYARL
1001 KGLSEKHVKA EMEQMALDVG LPSSKLKSKT SQLSGGMQRK LSVALAFVGG
1051 SKVVILDEPT AGVDPYSRRG IWELLKRYRQ GRTIILSTHH MDEADVLGDR
1101 IAIISHGKLC CVGSSLFLKN QLGTGYLTL VKKDVESSL SCRNSSTVS
1151 YLKKEDSVSQ SSSDAGLGSD HESDTLTIDV SAISNLIRKH VSEARLVEDI
1201 GHELTIVLPY EAAKEGAFVE LFHEIDDRLS DLGISSYGIS ETTLEEIFLK
1251 VAEESGVDAE TSDGTLPARR NRRAFGDKQS CLRPFTEDDA ADPNDSIDP
1301 ESRETDLLSG MDGKGSYQVK GWKLTQQQFV ALLWKRLIA RRSRKGFFAQ
1351 IVLPAVFVCI ALVFSLIVPP FGKYPSELEQ PWMYNEQYTF VSNDAPEDTG
1401 TLELLNALTK DPGFGTRCME GNPIPDTPCQ AGEEEWTTAP VPQTIMDLFQ
1451 NGNWTMQNPS PACQCSSDKI KKMLPVCPPG AGGLPPPQRK QNTADILQDL
1501 TGRNISDYLK KTYVQIIAKS LKNKIWVNEF RYGGFSLGVS NTQALPPSQE
1551 VNDATKQMKK HLKLAKDSSA DRFLNSLGRF MTGLDTRNNV KVWFNNKGWH
1601 AISSFLNVIN NAILRANLQK GENPSHYGIT AFNHPLNLTK QQLSEVAPMT
1651 TSVDVLVSIC VIFAMSFVPA SFVVFLIQR VSKAKHLQFI SGVKPVIYWL
1701 SNFVWDMCNY VVPATLVIII FICFQQKSYV SSTNLPVLAL LLLLYGWSIT
1751 PLMPASFVF KIPSTAYVVL TSVNLFIGIN GSVATFVLEL FTDNKLNNIN
1801 DILKSVFLIF PHFCLGRGLI DMVKNQAMAD ALERFGENRF VSPLSWDLVG
1851 RNLFAMAVEG VVFFLITVLI QYRFFIRPRP VNAKLSPLND EDEDVRRERQ
1901 RILDGGGQND ILEIKELTKI YRRKRKPAVD RICVGIPPGE CFGLLGVNGA
1951 GKSSTFKMLT GDTTVTRGDA FLNKNLSILSN IHEVHQNMGY CPQFDAITEL

```

- 7/10 -

2001 LTGREHVEFF ALLRGVPEKE VGKVGWAIK KLGLVKYGEK YAGNYSGGNK
2051 RKLSTAMALI GGPPVVFLDE PTTGMDPKAR RFLWNCALSV VKEGRSVVLT
2101 SHSMEECEAL CTRMAIMVNG RFRCLGQVQH LKNRFGDGYT IVVRIAGSNP
2151 DLKPVQDFFG LAFPGSVPEKE KHRNMLQYQL PSSLSSLARI FSILSQSKKR
2201 LHIEDYSVSQ TTLDQVFVNF AKDQSDDDHL KDLSLHKNQT VVDVAVLTSF
2251 LQDEKVKEYS V

**Figure 7: Images of the human cerebral cortex
labeled with anti-ABCA1 antibodies
and with DAPI**




Table 1 :

sample Δ (fold)
(temporal / frontal cortex)




Figure 8

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04058

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/53 G01N33/68 A01K67/027 A61K35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, EMBASE, Sequence Search, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 55318 A (UNIV BRITISH COLUMBIA ;XENON BIORESEARCH INC (CA)) 21 September 2000 (2000-09-21) page 46 - page 51; claim 34 -----	1-8, 11-15,20
X	US 2002 037843 A1 (LAM FRED CHIU-LAI ET AL) 28 March 2002 (2002-03-28) paragraph [0012] - paragraph [0019] paragraph [0042] paragraph [0095] - paragraph [0100] claim 8; example 1 -----	1-8, 11-15,20
X	US 6 225 525 B1 (LEUNG WAI-PING ET AL) 1 May 2001 (2001-05-01) abstract; figure 1 -----	8,11
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 July 2003

Date of mailing of the international search report

18. 09. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Aguilera, M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04058

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 2001 (2001-07), VAISMAN BORIS L ET AL: "ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice." XP002237202 Database accession no. PREV200100378305 abstract & JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 2, July 2001 (2001-07), pages 303-309, ISSN: 0021-9738	8,11
A	----- SCHMITZ G ET AL: "STRUCTURE, FUNCTION AND REGULATION OF THE ABC1 GENE PRODUCT" CURRENT OPINION IN LIPIDOLOGY, LONDON, GB, vol. 12, 2001, pages 129-140, XP002944249 ISSN: 0957-9672 the whole document	
A	----- RONALD AND NANCY REAGAN RESEARCH INSTITUTE ALZHEIMER'S ASSOCIATION AND NATIONAL INSTITUTE ON AGING WORKING GROUP: "Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". NEUROBIOLOGY OF AGING, vol. 19, no. 2, March 1998 (1998-03), pages 109-116, XP002233088 ISSN: 0197-4580 the whole document	
A	----- LAM FRED C ET AL: "beta-Amyloid efflux mediated by p-glycoprotein." JOURNAL OF NEUROCHEMISTRY, vol. 76, no. 4, February 2001 (2001-02), pages 1121-1128, XP002212665 ISSN: 0022-3042 the whole document	
A	----- EP 1 189 060 A (EVOTEC NEUROSCIENCES GMBH) 20 March 2002 (2002-03-20) the whole document -----	
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/04058

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	WOLLMER M AXEL ET AL: "ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease." NEUROBIOLOGY OF AGING. UNITED STATES 2003 MAY-JUN, vol. 24, no. 3, May 2003 (2003-05), pages 421-426, XP002237201 ISSN: 0197-4580 the whole document	
P,X	WO 02 057496 A (FEDEROFF HOWARD J ;ZLOKOVIC BERISLAV V (US); SOCRATECH L L C (US);) 25 July 2002 (2002-07-25) claim 1	1-8, 11-15,20
P,X	WO 02 101392 A (UNIV BRITISH COLUMBIA ;WELLINGTON CHERYL L (CA); BROOKS-WILSON ANG) 19 December 2002 (2002-12-19) claims 1-115	1-8, 11-15,20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/04058

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 9 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 10
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8, 11-15, 20

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10

Present claim 10 relates to a product defined by reference to a desirable characteristic or property, namely, that it is able to act as a "modulator" of an activity and/or level of an ABCA1 gene product. The claim covers all products having this characteristic or property, whereas the application does not provide any support within the meaning of EPC Article 6 and/or disclosure within the meaning of EPC Article 5 for any of such products. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claim also lacks clarity (Article 6 EPC). An attempt is made to define the products by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, no search has been carried out for claim 10.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-8, 11-15, 20

Methods for diagnosing or prognosing a neurodegenerative disease, and methods for screening for modulators of said diseases, which comprise determining a level and/or an activity of an ABCA1 gene product; recombinant non-human animals comprising a non-native sequence of said gene for use in the development of diagnostics and therapeutics of said diseases.

2. claim: 16

Method for testing a compound for inhibition of binding between a ligand and an ABCA1 translation product.

3. claim: 17

Method for testing a compound to determine the degree of binding to an ABCA1 translation product.

4. claim: 18 and 19

ABCA1 protein molecules

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/04058

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0055318	A	21-09-2000	AU 3832700 A	04-10-2000
			CA 2367955 A1	21-09-2000
			DE 1100895 T1	06-09-2001
			EP 1100895 A2	23-05-2001
			WO 0055318 A2	21-09-2000
			JP 2003513611 T	15-04-2003
			AU 1291901 A	26-03-2001
			CA 2382562 A1	08-03-2001
			EP 1239848 A2	18-09-2002
			WO 0115676 A2	08-03-2001
			JP 2003520780 T	08-07-2003

US 2002037843	A1	28-03-2002	AU 762593 B2	26-06-2003
			AU 1112800 A	15-05-2000
			CA 2348019 A1	04-05-2000
			EP 1123090 A1	16-08-2001
			JP 2002528411 T	03-09-2002
			WO 0024390 A1	04-05-2000
			AU 7260398 A	24-11-1998
			EP 0979086 A2	16-02-2000
			JP 2002504895 T	12-02-2002
			WO 9848784 A2	05-11-1998

US 6225525	B1	01-05-2001	AU 7871300 A	23-04-2001
			CA 2385154 A1	19-04-2001
			EP 1237405 A1	11-09-2002
			TR 200200975 T2	23-09-2002
			WO 0126453 A1	19-04-2001

EP 1189060	A	20-03-2002	EP 1189060 A1	20-03-2002

WO 02057496	A	25-07-2002	WO 02057496 A2	25-07-2002

WO 02101392	A	19-12-2002	WO 02101392 A2	19-12-2002

专利名称(译)	atp结合盒基因和蛋白质在神经退行性疾病中的诊断和治疗用途		
公开(公告)号	EP1495140A1	公开(公告)日	2005-01-12
申请号	EP2003720493	申请日	2003-04-17
申请(专利权)人(译)	EVOTEC NEUROSCIENCES GMBH		
当前申请(专利权)人(译)	EVOTEC NEUROSCIENCES GMBH		
[标]发明人	HESTERKAMP THOMAS VON DER KAMMER HEINZ KRAPPA RALF POHLNER JOHANNES		
发明人	HESTERKAMP, THOMAS VON DER KAMMER, HEINZ KRAPPA, RALF POHLNER, JOHANNES		
IPC分类号	A01K67/027 A61K35/00 A61K38/00 A61K45/00 A61K48/00 A61P25/00 A61P25/28 A61P43/00 C07K14/47 C07K14/705 C12N15/09 C12Q1/68 G01N33/15 G01N33/48 G01N33/50 G01N33/53 G01N33/68		
CPC分类号	A01K2217/05 A01K2227/105 A01K2267/0312 A61P25/00 A61P25/28 C07K14/705 C12Q1/6883 C12Q2600/158		
代理机构(译)	VON克莱斯勒SELTING WERNER		
优先权	2002008701 2002-04-18 EP 60/373375 2002-04-18 US		
外部链接	Espacenet		

摘要(译)

本发明公开了ABCA1基因在阿尔茨海默病患者特定脑区的差异表达。基于该发现，本发明提供了用于诊断或预测受试者中的神经变性疾病，特别是阿尔茨海默氏病，或用于确定受试者是否具有发展这种疾病的风险增加的方法。此外，本发明提供了使用ABCA1基因及其相应基因产物治疗或预防阿尔茨海默病和相关神经变性疾病的治疗和预防方法。还公开了筛选神经退行性疾病的调节剂的方法。